Materials and methods related to sodium/potassium adenosine triphosphase and cholesterol
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/92
C12Q-001/34
G01N-033/50
출원번호
US-0521864
(2011-01-13)
등록번호
US-8835171
(2014-09-16)
국제출원번호
PCT/US2011/021127
(2011-01-13)
§371/§102 date
20120802
(20120802)
국제공개번호
WO2011/088208
(2011-07-21)
발명자
/ 주소
Xie, Zi-Jian
Chen, Yiliang
Wang, Haojie
출원인 / 주소
The University of Toledo
대리인 / 주소
MacMillan, Sobanski & Todd, LLC
인용정보
피인용 횟수 :
0인용 특허 :
17
초록▼
This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation of new binding sites and interactions. The present invention provides practical applications of several s
This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation of new binding sites and interactions. The present invention provides practical applications of several surprising structural and functional relationships between Na/K ATPase and compounds which interact with Na/K ATPase. Disclosure of these structures and relationships provides insight and practical solutions to chemically affecting not only the Na/K ATPase interactions, but also regulators known to be upstream and downstream.
대표청구항▼
1. A method to affect cholesterol transport in a cell, comprising: administering to the cell a composition of matter comprising an amino acid compound of 17 residues comprising at least ten consecutive amino acid residues of a cholesterol recognition/interaction amino acid sequence and consensus pat
1. A method to affect cholesterol transport in a cell, comprising: administering to the cell a composition of matter comprising an amino acid compound of 17 residues comprising at least ten consecutive amino acid residues of a cholesterol recognition/interaction amino acid sequence and consensus pattern (CRAC) sequence having SEQ ID NO:2, or conservative substitutions of the at least ten consecutive amino acid residues of SEQ ID NO:2, wherein the compound is capable of binding cholesterol and affecting sodium/potassium adenosine triphosphate synthase (Na/K ATPase) cholesterol-binding activity by antagonizing the CRAC domain on an α1 subunit of Na/K ATPase. 2. The method of claim 1, wherein Na/K ATPase cholesterol-binding activity is affected in a manner selected from the group consisting of: decreasing; increasing; eliminating; periodically disrupting; and periodically enhancing. 3. A method to ameliorate neurodegeneration due to pathogenic intracellular cholesterol accumulation in a cell in need of such amelioration, comprising: administering to the cell a composition of matter comprising an amino acid compound of 17 residues comprising at least ten consecutive amino acid residues of a cholesterol recognition/interaction amino acid sequence and consensus pattern (CRAC) sequence having SEQ ID NO:2, or conservative substitutions of the at least ten consecutive amino acid residues of SEQ ID NO:2, wherein the compound is capable of binding cholesterol and decreasing the cholesterol binding activity of sodium/potassium adenosine triphosphate synthase (Na/K ATPase) by antagonizing the CRAC domain in an α1 subunit of Na/K ATPase. 4. A method of treating Niemann Pick, type C1 disease, comprising: administering to the cell a composition of matter comprising an amino acid compound of 17 residues comprising at least ten consecutive amino acid residues of a cholesterol recognition/interaction amino acid sequence and consensus pattern (CRAC) sequence having SEQ ID NO:2, or conservative substitutions of the at least ten consecutive amino acid residues of SEQ ID NO:2, wherein the compound is capable of binding cholesterol and decreasing the ability of sodium/potassium adenosine triphosphate synthase (Na/K ATPase) to bind to cholesterol by antagonizing the CRAC domain of an α1 subunit of Na/K ATPase. 5. The method of claim 4, wherein the decrease is accomplished by inhibiting the CRAC domain of the α1 subunit of Na/K ATPase. 6. A method to identify compositions capable of treating cholesterol-related disease states, comprising a) contacting a test sample with a composition comprising an amino acid compound of 17 residues comprising at least ten consecutive amino acid residues or conservative substitutions of the at least ten consecutive amino acid residues of a cholesterol recognition/interaction amino acid sequence and consensus pattern (CRAC) domain in an α1 subunit of Na/K ATPase having SEQ ID NO:2; andb) identifying if step a) results in antagonizing the ability of cholesterol to bind to the CRAC domain of the α1 subunit of Na/K ATPase. 7. A method to identify compositions capable of treating at least one disease state, comprising a) contacting a test sample with a composition comprising an amino acid compound of 17 residues comprising at least ten consecutive amino acid residues or conservative substitutions of the at least ten consecutive amino acid residues of a cholesterol recognition/interaction amino acid sequence and consensus pattern (CRAC) domain in an α1 subunit of Na/K ATPase having SEQ ID NO:2; andb) identifying if step a) results in antagonizing the ability of cholesterol to bind to the CRAC domain of the α1 subunit of Na/K ATPase, wherein the disease state is selected from the group consisting of: NPC1; pathogenic lipid accumulation; vascular disease; heart attack; stroke; overweight; obesity; diabetes; metabolic syndrome; thyroid malfunction; medication side effect; atherosclerosis; heart failure; heart disease; Alzheimer's disease; Parkinson disease; Huntington disease; Tay Sachs disease and neurodegenerative disease. 8. A method to affect the trafficking and expression of caveolin-1 in a cell, comprising: administering to the cell, a composition of matter comprising an amino acid compound of 17 residues comprising at least ten consecutive amino acid residues of a cholesterol recognition/interaction amino acid sequence and consensus pattern (CRAC) sequence having SEQ ID NO:2, or conservative substitutions of the at least ten consecutive amino acid residues of SEQ ID NO:2, wherein the compound is capable of binding cholesterol and down-regulating plasma membrane α1 subunit of sodium/potassium adenosine triphosphate synthase (Na/K ATPase) the Na/K ATPase having the CRAC domain in an α1 subunit of Na/K ATPase. 9. A method to treat Niemann Pick, type C1 disease (NPC1 disease), comprising: administering to a subject having Niemann Pick, type C1 disease, a composition of matter comprising an amino acid compound of 17 residues comprising at least ten consecutive amino acid residues of a cholesterol recognition/interaction amino acid sequence and consensus pattern (CRAC) sequence having SEQ ID NO:2, or conservative substitutions of the at least ten consecutive amino acid residues of SEQ ID NO:2, wherein the compound is capable of binding cholesterol and altering expression of the α1 subunit of sodium/potassium adenosine triphosphate synthase (Na/K ATPase) the Na/K ATPase having the CRAC domain in an α1 subunit of Na/K ATPase so as to ameliorate the symptoms of NPC1 disease. 10. The method of claim 1, wherein the cell is a mammal cell. 11. The method of claim 3, wherein the cell is a mammal cell. 12. The method of claim 8, wherein the cell is a mammal cell. 13. The method of claim 10, wherein the mammal cell is selected from the group consisting of: liver cells; kidney cells; brain cells; nerve cells; pancreatic cells; lung cells; skin cells; heart cells; rodent cells; human cells; mouse cells; rat cells; guinea pig cells; dog cells; and, monkey cells. 14. The method of claim 11, wherein the mammal cell is selected from the group consisting of: liver cells; kidney cells; brain cells; nerve cells; pancreatic cells; lung cells; skin cells; heart cells; rodent cells; human cells; mouse cells; rat cells; guinea pig cells; dog cells; and, monkey cells. 15. The method of claim 12, wherein the mammal cell is selected from the group consisting of: liver cells; kidney cells; brain cells; nerve cells; pancreatic cells; lung cells; skin cells; heart cells; rodent cells; human cells; mouse cells; rat cells; guinea pig cells; dog cells; and, monkey cells.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (17)
Larson, Drake, Catechin multimers as therapeutic drug delivery agents.
Shan,Jacqueline J.; Wu,Xi Chen; Pang,Peter K. T.; Ling,Lei, Hypericin andextract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics.
Zhao,Jian; Zhou,Rui; Chen,Hu, Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof.
Ji, Joon Whan; Kang, Jae Ku; Kim, Young Hoon; Jung, Sung Hak; Cho, Hee Jae; Lee, Kwang Hyuk, Pharmaceutical composition for preventing and treating erectile impotence using purified sumsoo extract.
Appelgren Curt H. (V Frlunda SEX) Bogentoft Conny B. (Kallered SEX), Pharmaceutically preparation comprising a cardiac glycoside in combination with a polymer.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.